loading page

Biological treatment provides disease-modifying immunological effects
  • +2
  • Mohamed Shamji,
  • Elizabeth Palmer,
  • Janice Layhadi,
  • Theo Moraes,
  • Thomas Eiwegger
Mohamed Shamji
Imperial College London
Author Profile
Elizabeth Palmer
Imperial College London
Author Profile
Janice Layhadi
Imperial College London
Author Profile
Theo Moraes
University of Toronto
Author Profile
Thomas Eiwegger
The Hospital for Sick Children
Author Profile

Abstract

Advances in molecular biology alongside the accelerated development of gene and cell engineering have contributed to the development of several endotype-targeted biological therapies against chronic immune-mediated allergic diseases. Conventional therapies for asthma, chronic rhinosinusitis with polyposis (CRSwNP), chronic spontaneous urticaria and atopic dermatitis (AD) are not without limitations, and as such the advent of biological therapies have provided a promising alternative treatment option. Biologicals have proven efficacious in the treatment of refractory chronic spontaneous urticaria, asthma, AD, CRSwNP and there is increasing evidence for their utility in treating food allergy. Biologicals are applied and investigated for the most urgent need: acute treatment, symptom control and reduction of steroid usage. Currently there are five approved biologicals for allergic disease management, targeted against IgE (omalizumab), type 2 (T2) cytokines and cytokine receptors (IL-4Ra; dupilumab, IL-5; mepolizumab/reslizumab, IL-5Ra; benralizumab).

Peer review status:ACCEPTED

31 Mar 2021Submitted to Allergy
01 Apr 2021Submission Checks Completed
01 Apr 2021Assigned to Editor
03 Apr 2021Reviewer(s) Assigned
07 Apr 2021Review(s) Completed, Editorial Evaluation Pending
08 Apr 2021Editorial Decision: Revise Minor
05 May 20211st Revision Received
08 May 2021Submission Checks Completed
08 May 2021Assigned to Editor
11 May 2021Reviewer(s) Assigned
14 May 2021Review(s) Completed, Editorial Evaluation Pending
16 May 2021Editorial Decision: Accept